Their ability to bind different and apparently unrelated ligands [48] raises the possibility that FPR agonists/inverse agonists or antagonists could be considered as novel anti-inflammatory therapeutics for the treatment of a variety of clinical conditions, including neurodegenerative disease and stroke [48]. Here, FPR1 is linked to stroke disorder.